4D-150 Clinical Activity and Tolerability - 4D-150 demonstrates robust and durable clinical activity across all studied populations, including recently diagnosed patients with wet AMD[7] - 4D-150 exhibits a tolerability profile comparable to approved anti-VEGF agents[8] 4D-150 Injection-Free Rates in Wet AMD - In the severe wet AMD population, 44% of patients were injection-free through 52 weeks, with 48% requiring >1 injection and 8% requiring 1 injection, resulting in an 83% treatment burden reduction[13] - In the broad wet AMD population (including recently diagnosed), 70% of patients were injection-free through 52 weeks, with 20% requiring >1 injection and 10% requiring 1 injection, resulting in an 89% treatment burden reduction[16] - In the recently diagnosed wet AMD population, 87% of patients were injection-free through 52 weeks, with 13% requiring 1 injection, resulting in a 98% treatment burden reduction[19] 4D-150 Intraocular Inflammation (IOI) Profile - 4D-150 development is enabled by a favorable IOI profile, with IOI rates of 2-3%[22] 4FRONT Phase 3 Program Design - The 4FRONT Phase 3 program in treatment-naïve wet AMD is designed to maximize the probabilities of clinical, regulatory, and commercial success[10, 24, 35] - The 4FRONT-1 Phase 3 study's primary endpoint is BCVA noninferiority of 4D-150 3E10 vg/eye to Aflibercept 2mg Q8 weeks[33]

Business Overview - Solaris Energy Infrastructure has a market capitalization of approximately $1.5 billion and an enterprise value of approximately $2.0 billion[4] - The company anticipates its power solutions segment to contribute over 80% of its Adjusted EBITDA, while logistics solutions are expected to contribute less than 20%[6, 9] Growth and Expansion - Solaris expects to grow its fleet to 1.7 GW by the second half of 2027, with 71% of the pro forma fleet already contracted[10, 13] - The company has established a joint venture with a key data center customer for approximately 900 MW of power generation[18] - Additional orders for 330 MW will expand the fleet to approximately 1.7 GW by 2H 2027[13] Financial Performance and Projections - Solaris anticipates an annual Adjusted EBITDA contribution of $575-600 million pro forma for power fleet equipment deliveries[22] - The company projects a potential annual Adjusted EBITDA of $440-465 million from its 1.7 GW power solutions fleet[22] - Q1 2025 Adjusted EBITDA was $47 million, with Q2 2025 guidance between $50-55 million and Q3 2025 guidance between $55-60 million[93] Fleet Composition - The pro forma 1.7 GW fleet includes 55% of 16.5 MW units and 37% of units greater than 35 MW[52] - Approximately 67% of the 1.7 GW fleet is contracted to data centers, with 4% contracted to energy and 29% available beginning in 2H 2026[44]

Company Overview - Ryan Specialty Group (RSG) is a rapidly growing provider of specialty products and solutions for insurance brokers, agents, and carriers[11] - RSG was founded in 2010[12] - As of September 30, 2021, RSG's LTM (Last Twelve Months) revenue was $1.4 billion[12] - RSG is the 2nd largest U S P&C wholesale broker[12] Financial Performance - RSG's organic revenue growth for the period ending September 30, 2021, YTD (Year-to-Date) was 25 6%[12] - RSG's LTM total revenue growth as of September 30, 2021, was 51 6%[12] - The Adjusted EBITDAC for LTM was $442 million[49] - The Adjusted EBITDAC Margin was 32 0%[49] Market Position and Growth Strategy - 71% of RSG's premiums are placed in the attractive E&S (Excess & Surplus) market[19] - The E&S market has experienced a CAGR (Compound Annual Growth Rate) of 6 4% compared to the admitted market's CAGR of 4 0% over the past decade[21] - RSG's revenue growth with the top 100 retail brokerage firms exceeded RSG's organic revenue growth of 20% in 2020[31] - RSG has completed over 40 acquisitions since its founding[31]

Company Overview - Ryan Specialty Group (RSG) was founded in 2010 and has grown to $1 billion in revenue by 2020[12] - RSG is the 2nd largest U S P&C wholesale broker and the largest U S P&C MGU[12] - The company experienced 20% organic revenue growth in 2020[12] - Total revenue growth in 2020 was 33%[12] Market Position and Strategy - 71% of RSG's premiums are placed in the E&S market[20] - The E&S market has a Compound Annual Growth Rate (CAGR) of 6 4% compared to the admitted market's 4 0% over the past decade[23] - RSG's revenue growth with the top 100 retail brokerage firms exceeded RSG's organic revenue growth of 20% in 2020[31] - Approximately $59 million of revenue was acquired in 2019, and $240 million in 2020 through strategic acquisitions[31] Financial Performance - Adjusted EBITDAC increased from $191 million in 2019 to $294 million in 2020[40] - The Adjusted EBITDAC Margin increased from 25% in 2019 to 29% in 2020[40] - The company's revenue increased from $765 million in 2019 to $1 018 billion in 2020[40]

Targa's Value Proposition and Growth - Targa is the largest gatherer and processor in the Permian Basin, driving integrated returns through NGL pipeline transportation, fractionation, and LPG exports[9] - The company has experienced significant volume growth, with a +24% CAGR in fractionation volumes and +12% CAGR in LPG export volumes from FY 2019 to YTD 3Q24[12] - Permian natural gas inlet volumes have grown at a +25% CAGR from Q4 2019 to YTD 3Q24[16] - Targa's adjusted EBITDA has grown by +182% since 2019, driven by its integrated NGL business and strong business fundamentals[19] Financial Performance and Shareholder Returns - Management expects to recommend to Targa's Board of Directors an increase to the 2025 quarterly cash common dividend to $4.00 per share annualized for the first quarter of 2025, representing a +33% YoY increase[9, 10] - Targa has repurchased over 202 million shares since October 2020 at a weighted average price of ~$7069[19] - The company's 2024E fee-based volumes in G&P are approximately ~90%[9, 66] - Targa expects to return 40-50% of adjusted cash flow from operations across a multi-year horizon[75] Permian Basin and Infrastructure - Targa has a premier Permian asset footprint with ~88 Bcf/d gross processing capacity across 43 plants[26, 27, 80] - The company is expanding its Permian G&P footprint, with several new plants scheduled to come online between 1Q25 and 3Q26[32, 94] - Targa's Daytona NGL Pipeline has a capacity of 400 MBbl/d and was expected to be in service in 3Q24[95]

Market Opportunity & Growth - The company is a global leader in therapeutic ultrasound for cancer and benign diseases, with a strong growth opportunity in urology and prostate cancer[4,6] - Prostate cancer is the most common cancer among men in the US, with 33 million American men living with it in 2025, and 313780 new cases diagnosed[14,15] - Globally, there are approximately 15 million new prostate cancer cases per year as of 2022, with Europe accounting for 473011 cases, Asia for 386424 cases, and North America for 255782 cases[19,20] - The annual procedure opportunity for Focal One HIFU in prostate cancer is estimated at 470000 globally, including 165000 in Europe, 130000 in Asia, and 100000 in North America[25] Clinical Evidence & Technology - Over 1000 peer-reviewed publications support HIFU in the treatment of prostate cancer[36] - A comparative study (HIFI) showed comparable cancer control with HIFU (90% STFS) versus radical prostatectomy (86% STFS), with superior functional outcomes for HIFU[41,45] - A randomized controlled trial (FARP) demonstrated equivalent oncologic control at 3 years (935% TFF for Focal Ablation vs 915% for Radical Prostatectomy) and superior functional outcomes after focal ablation[54] - The company's Focal One system has 11 systems in the NY/NJ MSA at the end of 2024 and 67 systems in the US at the end of Q1 2025[104,107] Reimbursement & Expansion - Medicare reimbursement for HIFU is $9247 in 2025, a 54% increase, and physician payment is $951[70,73] - The company is targeting large incidence cancer and benign conditions, including 15 million prostate cancer cases, 113 million BPH cases, and 205 million rectal endometriosis cases[89]

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care[8] - The company operates a SaaS platform to manage patient intake and offers an integrated patient payments solution[8] - Phreesia processed $1.4 billion in patient payments in FY19[8] - The company serves approximately 1,600 healthcare provider organizations[8, 22] Financial Performance and Market Opportunity - Phreesia's revenue in FY19 was $100 million, demonstrating over 25% growth[8, 9] - The company estimates a total addressable market (TAM) of approximately $7 billion[9] - Subscription and related services accounted for 44% of FY19 revenue, while payment processing contributed 37%, and life sciences 19%[34] - In Q2 2020, total revenue reached $30.8 million, a 24.4% increase compared to Q2 2019[42] Growth Strategy - Phreesia aims to land new clients, grow its footprint within existing clients, and cross-sell new applications[27] - The company focuses on margin expansion through scale and strategic partnerships and M&A[27] - Phreesia achieved a 107% dollar-based net retention rate in FY19[27]

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care[12] - The company processes approximately $1.9 billion in patient payments in FY20[12] - Phreesia's revenue in FY20 was $125 million, representing a 25% growth[12] - The company estimates a total addressable market of approximately $9 billion[13] Financial Performance - Total revenue increased from $99.9 million in FY2019 to $124.8 million in FY2020, a 25% year-over-year growth[51] - Subscription and related services revenue was $56.4 million in FY2020[51], which accounts for 45% of FY20 revenue[44] - Payment processing revenue was $46.5 million in FY2020, representing 37% of FY20 revenue[44] - Life Sciences revenue contributed $21.9 million in FY2020, accounting for 18% of FY20 revenue[44] - Adjusted EBITDA increased from $3.5 million in FY2019 to $4.8 million in FY2020[53] Key Metrics - The average number of provider clients increased by 5% from 1,490 in FY19 to 1,571 in FY20[47]

IBTROZI (Taletrectinib) - IBTROZI获美国FDA批准用于治疗ROS1+ NSCLC[5,7,14,101] - IBTROZI还在中国获批用于治疗ROS1+ NSCLC[5,14,101] - IBTROZI对TKI-naive患者显示出高且持久的反应，中位DOR尚未达到[19,20] - IBTROZI在TKI预处理患者中也显示出显著效果，TRUST-II研究中ORR为62%[23,24] - IBTROZI具有良好的安全性，仅7%的患者因TEAEs导致停药[26] - IBTROZI对ROS1的选择性是TRKb的11-20倍[32] - 美国每年约有3000例新诊断的ROS1+ NSCLC患者[42] - IBTROZI的定价约为每年35万美元[42] - 理论上，美国ROS1+ NSCLC市场机会总额约为38亿美元[40] Safusidenib - Safusidenib将于2025年进入关键性研究，用于治疗弥漫性IDH1突变型胶质瘤[5,6,56] - Royalty Pharma以9.05亿美元收购了Vorasidenib未来美国销售额15%的特许权使用费[61,67] - 在低级别胶质瘤的早期研究中，Safusidenib的反应率是Vorasidenib在关键性INDIGO研究中的3倍[68,69] NUV-1511 - NUV-1511是一种DDC，正在进行1/2期研究，用于治疗晚期实体瘤[5,6,79,93] Financial Position - 截至2025年3月31日，Nuvation Bio拥有4.62亿美元的现金储备[5,102] - Nuvation Bio通过与Sagard Healthcare Partners的合作，获得了高达2.5亿美元的非稀释性资本[5,102,103]

Valaris Overview - Valaris has the largest offshore drilling fleet with 49 rigs, including 15 high-spec floaters and 34 jackups[4] - The company's contract backlog stands at $4.2 billion as of April 30, 2025[4] - Valaris anticipates FY 2025 EBITDA in the range of $500 million to $560 million[4] - Valaris' drillship fleet is comprised of 92% 7th generation assets (12 out of 13)[4] - Valaris has maintained a revenue efficiency of 96%+ for four consecutive years[4] Fleet Positioning and Demand - The Golden Triangle is expected to account for 70% of benign environment floater demand through 2029[5] - Jackup fleet is primarily positioned in the North Sea (57%) and Middle East (19% excluding Saudi Arabia)[13] - Benign environment floater demand in 2026-2028 is expected to be ~10% higher on average compared to 2024-2025[34] Financial Performance and Strategy - $325 million has been returned to shareholders since the start of the share repurchase program in 2023[45]